The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -15,804,655 |
| Stock based compensation | 1,147,236 |
| Amortization of intangibles | 100,000 |
| Realized and unrealized gain and accrued interest on investments | 215,855 |
| Increase (decrease) in accounts payable and accrued expenses | 1,325,128 |
| Decrease in prepaid expenses and other assets | 92,848 |
| Net cash used in operating activities | -13,540,994 |
| Purchase of investments | 12,264,069 |
| Proceeds from redemption of investments | 7,986,294 |
| Net cash used by investing activities | -4,277,775 |
| Payment of amounts due to officers | 600,000 |
| Proceeds from sale of equity securities, net | 18,614,135 |
| Net cash provided by financing activities | 18,014,135 |
| Effect of foreign exchange rate on changes on cash | -613 |
| Net change in cash and cash equivalents | 194,753 |
| Cash and cash equivalents - beginning of year | 3,623,343 |
| Cash and cash equivalents - end of year | 3,818,096 |
Quoin Pharmaceuticals, Ltd. (QNRX)
Quoin Pharmaceuticals, Ltd. (QNRX)